Haploidentical bone marrow transplantation without T-cell depletion.

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Haploidentical bone marrow transplantation (BMT) traditionally required T-cell depletion.
• Graft-versus-host disease (GVHD) and engraftment challenges have limited BMT options.
• Ex vivo T-cell depletion is technically demanding and costly.

Purpose of the Study:

• To review immune reconstitution and clinical outcomes of unmanipulated haploidentical hematopoietic stem cell transplantation (HSCT).
• To compare outcomes of unmanipulated haploidentical HSCT with other donor sources.
• To discuss strategies for improving outcomes in unmanipulated haploidentical BMT.

Main Methods:

• Review of transplant strategies including anti-thymocyte globulin (ATG), G-CSF primed grafts, rapamycin, and high-dose cyclophosphamide (Cy).
• Analysis of immune reconstitution and clinical outcomes.
• Comparative analysis with HLA-matched sibling donor (MSD), HLA-matched unrelated donor (MUD), and double umbilical cord blood (dUCB) transplantation.

Main Results:

• New strategies enable fast hematologic engraftment across the HLA barrier.
• Acceptable incidence of GVHD achieved with these approaches.
• Unmanipulated transplantation shows promise as a cost-effective alternative.

Conclusions:

• Unmanipulated haploidentical HSCT is a feasible alternative to T-cell depleted methods.
• Further strategies can enhance outcomes in unmanipulated haploidentical BMT.
• This approach may reduce technical complexity and cost in BMT.